Recurrent colon perforation after discontinuation of bevacizumab for ovarian cancer

Bevacizumab (Bev) is an antiangiogenic drug used to treat various malignances, including ovarian cancer (OC). Bev is generally well-tolerated; however, it has a characteristic toxicity profile. In particular, gastrointestinal perforation (GIP) is a rare but serious side effect that can be lethal. A...

Descripción completa

Detalles Bibliográficos
Autores principales: Nonaka, Michiko, Sato, Seiya, Osaku, Daiken, Sawada, Mayumi, Kudoh, Akiko, Chikumi, Jun, Sato, Shinya, Oishi, Tetsuro, Harada, Tasuku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116855/
https://www.ncbi.nlm.nih.gov/pubmed/30175211
http://dx.doi.org/10.1016/j.gore.2018.08.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116855/
https://www.ncbi.nlm.nih.gov/pubmed/30175211
http://dx.doi.org/10.1016/j.gore.2018.08.005

Ejemplares similares